Singapoo - Kiingereza - HSA (Health Sciences Authority)

pierre fabre singapore pte ltd - encorafenib - capsule - encorafenib 50mg

Singapoo - Kiingereza - HSA (Health Sciences Authority)

pierre fabre singapore pte ltd - encorafenib - capsule - encorafenib 75mg

Singapoo - Kiingereza - HSA (Health Sciences Authority)

pierre fabre singapore pte ltd - binimetinib - tablet, film coated - binimetinib 15mg

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

agilent technologies australia pty ltd - ct1056 - immunohistology cell marker ivds - pd-l1 ihc 28-8 pharmdx is a qualitative immunohistochemical assay using monoclonal rabbit anti-pd-l1, clone 28-8 intended for use in the detection of pd-l1 protein in formalin-fixed, paraffin-embedded (ffpe) cancer tissues using envision flex visualization system on autostainer link 48. pd-l1 ihc 28-8 pharmdx is a qualitative immunohistochemical assay using monoclonal rabbit anti-pd-l1, clone 28-8 intended for use in the detection of pd-l1 protein in formalin-fixed, paraffin-embedded (ffpe) non-squamous non-small cell lung cancer (nsnsclc), melanoma, and esophageal squamous cell carcinoma (escc) tissues. it is indicated as an aid in identifying escc patients with tumour cell pd-l1 expression ? 1% for treatment with opdivo? (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy or opdivo? (nivolumab) in combination with yervoy? (ipilimumab).